/
Psychiatry
Bipolar Disorder
32
Pipeline Programs↗
45
Active Trials↗
30
Companies Involved↗
Bipolar Disorder is a moderately active landscape with 32 programs across 30 companies. The most active players are Nanjing Chia-tai Tianqing Pharmaceutical, Vanda Pharmaceuticals, Otsuka. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical27
Phase 1
No programs
Approved
No programs
Analysis
Modality Breakdown
97%
Small molecule
30 of 31 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 31 classified programs, each share of the total. Modality classified for 97% of 32 pipeline programs.
Analysis
Trial Status
278
clinical trials
Completed175 · 63%
Recruiting31 · 11%
Terminated25 · 9%
Unknown status24 · 9%
Not yet recruiting9 · 3%
Withdrawn9 · 3%
Other5 · 2%
Clinical Trials
Trial Activity
278 trials
B-HAPPI: Bipolar Disorder and High-dose Adjunctive Pramipexole in Anhedonic Depression - a Phase III, Double-blind, Randomized Controlled Trial
Recruiting·—·Phase 3·NCT07664852·126 enrolled
A Randomized, Double-Blind, Placebo-Controlled Study Followed by Open-Label Treatment of ALTO-100 in Adults With Bipolar Disorder Currently Experiencing a Major Depressive Episode
Recruiting·—·Phase 2·NCT06656416·200 enrolled
Page 1 of 19
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)